SEC Comment Letter 0000000000-24-004172 to MetaVia Inc. (MTVA)
MetaVia Inc.
Date: April 17, 2024 · CIK: 0001638287 · Accession: 0000000000-24-004172
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278646
Letter
United States securities and exchange commission logo April 17, 2024 Hyung Heon Kim President and Chief Executive Officer NeuroBo Pharmaceuticals, Inc. 545 Concord Avenue, Suite 210 Cambridge, MA 02138 Re:NeuroBo Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed April 12, 2024 File No. 333-278646 Dear Hyung Heon Kim: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Phil Torrence, Esq.
Show Raw Text
United States securities and exchange commission logo
April 17, 2024
Hyung Heon Kim
President and Chief Executive Officer
NeuroBo Pharmaceuticals, Inc.
545 Concord Avenue, Suite 210
Cambridge, MA 02138
Re:NeuroBo Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed April 12, 2024
File No. 333-278646
Dear Hyung Heon Kim:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Phil Torrence, Esq.